Standout Papers

Pembrolizumab versus docetaxel for previously... 2003 2026 2010 2018 4.8k
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (2015)
    Roy S. Herbst, Paul Baas et al. The Lancet
  2. The biology and management of non-small cell lung cancer (2018)
    Roy S. Herbst, Daniel Morgensztern et al. Nature
  3. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer (2003)
    Mark G. Kris, Ronald B. Natale et al. JAMA
  4. Lung Cancer (2008)
    Roy S. Herbst, John V. Heymach et al. New England Journal of Medicine
  5. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2004)
    David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology
  6. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 (2004)
    Giuseppe Giaccone, Roy S. Herbst et al. Journal of Clinical Oncology
  7. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 (2004)
    Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology
  8. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib (2005)
    David A. Eberhard, Bruce E. Johnson et al. Journal of Clinical Oncology
  9. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer (2005)
    Roy S. Herbst, Diane Prager et al. Journal of Clinical Oncology
  10. Review of epidermal growth factor receptor biology (2004)
    Roy S. Herbst International Journal of Radiation Oncology*Biology*Physics
  11. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer (2015)
    Joseph McLaughlin, Gang Han et al. JAMA Oncology
  12. Programmed death ligand-1 expression in non-small cell lung cancer (2013)
    Vamsidhar Velcheti, Kurt A. Schalper et al. Laboratory Investigation
  13. Toward personalized treatment approaches for non-small-cell lung cancer (2021)
    Meina Wang, Roy S. Herbst et al. Nature Medicine
  14. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials (2005)
    Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology
  15. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy (2019)
    Jun Wang, Jingwei Sun et al. Nature Medicine
  16. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes (2019)
    Deborah B. Doroshow, Miguel F. Sanmamed et al. Clinical Cancer Research
  17. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma (2017)
    Chee Khoon Lee, Johnathan Man et al. JAMA Oncology
  18. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA (2018)
    Sarah B. Goldberg, Azeet Narayan et al. Clinical Cancer Research
  19. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC (2023)
    Masahiro Tsuboi, Roy S. Herbst et al. New England Journal of Medicine
  20. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities (2022)
    Tae Kon Kim, Esten N. Vandsemb et al. Nature Reviews Drug Discovery
  21. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC (2021)
    Roy S. Herbst, Edward B. Garon et al. Journal of Thoracic Oncology
  22. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC (2021)
    Michael J. Grant, Roy S. Herbst et al. Nature Reviews Clinical Oncology
  23. Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A (2022)
    Karen L. Reckamp, Mary W. Redman et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 22 from Science/Nature 178 standout
Sub-graph 1 of 16

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
9 intermediate papers

Works of Roy S. Herbst being referenced

Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
2020
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
and 9 more

Author Peers

Author Last Decade Papers Cites
Roy S. Herbst 31201 25944 16614 573 49.6k
Kenneth J. Pienta 17615 17167 21478 662 48.6k
Hope S. Rugo 30324 15990 10917 833 43.5k
Jean‐Charles Soria 19265 12561 12792 675 34.0k
Fabrice André 19923 12659 13587 667 36.8k
James Chih‐Hsin Yang 45338 33267 18171 692 64.9k
Johann S. de Bono 21920 28295 18601 1.0k 51.9k
Bruce E. Johnson 29340 28871 20418 411 49.7k
Tony Mok 34880 38626 15477 671 55.0k
Bernard Escudier 14176 26197 22473 712 40.8k
Vincent A. Miller 29326 30167 15829 476 44.8k

All Works

Loading papers...

Rankless by CCL
2026